Femtech: The Underfunded Segment of Women's Health and Its Market Potential

• Femtech, short for female technology, represents a growing sector of digital technologies dedicated to women's health and wellness.
• Women receive diagnoses much later, creating a massive market gap and an opportunity to bring innovation to the next level.
• Startups founded by women — and founders who want to serve women and underserved communities more broadly — frequently face significant barriers in securing early-stage funding.
• Funds like Aegis Capital actively monitor and support this historically underinvested market segment, investing in founders who are building for women, both in clinical and consumer-facing products.
• Artificial intelligence and early diagnostics provide highly convincing arguments for venture capital investors, particularly those able to ensure sustainable returns while helping improve patient outcomes.

What is femtech and why is this segment growing?

Defining the category involves looking at software and diagnostic technologies dedicated entirely to female physiology, and access to care across reproductive health, sexual health, sexual wellness, and menstrual health. The rapid expansion of this sector directly responds to the historically ignored needs of half the global population. Implementing digital technology in women's health addresses long-standing gaps in medical research and daily care.

Analyzing market data reveals exactly why this specific segment continues to expand at a rapid pace. Medical professionals diagnose females significantly later, often delaying cancer detection by over 2 years and diabetes by over 4 years. Women report 52 percent more adverse drug reactions than men. Are you surprised that such a fundamental part of the whole population's life has been overlooked for so long? Expanding the femtech ecosystem helps correct these systemic delays and improves patient safety.

Definition and scope of software and medical devices

Classifying technological solutions within the female health market requires understanding the different layers of available products. Developers currently focus on creating integrated systems that bridge the gap between physical hardware and cloud-based analytics, and digital health platforms that connect patients to care. Buyers can choose from several primary categories of medical and lifestyle tools:

• smart women's health devices combining physical hardware with a secure digital infrastructure
• advanced analytical software supporting early diagnostics and personalized treatment plans in reproductive health and sexual health
• telemedicine platforms facilitating immediate access to specialized medical care, menstrual health tracking, and consultations

Main categories of the femtech market and innovation breakdown

Exploring the main market pillars reveals a wide range of medical and lifestyle solutions designed specifically for female physiology. Statistics show that while females in the European Union live longer than males on average, the actual number of healthy life years remains almost identical. Modern companies increasingly offer workplace fertility benefits to support their employees through complex family planning journeys.

Corporate capital flows toward innovations aimed specifically at changing these grim statistics and elevating the overall quality of life. Women spend a larger portion of their lives in poor health, creating a massive market need for targeted medical solutions. Founders operating in the femtech space continuously develop new methodologies to address these specific physiological challenges, and to bring services that were previously out of reach to more communities.

Solutions for longevity and chronic diseases

Digital tools actively support patients during menopause, bringing innovative technologies to a previously overlooked demographic. Developers create specialized software that addresses long-term wellness rather than just immediate symptom relief. Investment funds typically direct their attention toward three specific areas of technological advancement:

• longevity solutions focusing primarily on extending the number of healthy life years through a digital menopause care platform
• chronic disease care systems utilizing a highly personalized, data-driven treatment approach
• diagnostic innovations shifting medical interventions to an earlier stage via a mobile reproductive healthcare platform

Why do femtech startups struggle to secure early-stage funding?

Historical underfunding of the female medicine segment stems from deeply rooted systemic biases within the medical and financial sectors. Researchers have consistently marginalized female physiology, leading to a massive knowledge gap in modern healthcare. Founders face several distinct barriers when attempting to secure capital for their projects:

• lack of adequate female representation in clinical trials, where they make up only about one-third of cardiology trial participants
• drastic underfunding of research on female-specific diseases, where a mere 4 percent of funding for coronary artery disease goes to studies involving women
• an educational and cognitive gap among investment decision-makers, hindering the proper assessment of this underfunded segment during early-stage funding rounds

The Venture Capital funding gap for female founders

Important: A lack of understanding of women's specific health issues by traditional investment structures significantly slows down innovation development. The exceptionally low percentage of female partners within financial institutions creates a massive barrier to accurate market potential assessment by analysts. Decision-makers often fail to grasp the commercial viability of products designed for unfamiliar physiological needs.

Conscious investors actively seek out modern solutions to bridge these glaring financial and educational gaps in the market. Specialized femtech investors continuously educate the broader financial community about the untapped potential of female-focused medical software. Directing capital toward diverse founding teams — women and men working together — ultimately yields better financial returns and more effective healthcare products. Initiatives in hubs like London are helping founders join a growing network of like-minded investors and sisters in the industry who want to see the sector explore its full potential.

How to secure capital for innovations in women's health?

Multiple sources of external capital exist for founders developing new innovations in the female health sector. Commercialization paths typically lead from university spinouts through public grant programs all the way to high-risk financial institutions. Securing equity investment requires a solid business plan and a clear demonstration of clinical efficacy — and, over time, a track record that carries a founder from a seed round through a Series A and beyond.

Specialized funds like Aegis Capital offer early-stage financing specifically tailored for pre-seed and seed rounds. Initial support can amount to 3 million PLN, with the possibility of increasing to 8 million PLN in subsequent rounds. Additional funding options often include European grants ranging from 0.5–2 million EUR for highly scalable medical technologies.

Capital support from Venture Capital funds

Financial institutions offer ambitious founders much more than just raw monetary capital to scale their operations. Partnering with established venture capital firms provides strategic advantages that accelerate product development and market penetration, providing advice drawing on years of sector experience. Accelerators and incubators typically provide the following growth-oriented benefits:

• direct access to an active ecosystem of medical innovators and experienced healthcare experts
• participation in dedicated industry events and specialized workshops facilitating expansion into foreign markets
• structural support in building strategic partnerships with large corporations and recognized research institutions

Artificial intelligence and Big Data analytics as an argument for investors

Collecting and processing massive datasets remains crucial for proving the commercial potential of medical projects to financial backers. Artificial intelligence allows physicians to precisely diagnose complex conditions long before the very first physical symptoms appear. Implementing a detailed big data analytics dashboard helps founders visualize clinical outcomes for potential stakeholders.

Integrating raw clinical data with daily lifestyle information fundamentally alters the basic economics of modern healthcare. Investors actively seek solutions that shift medical intervention to a much earlier, preventative stage. Backing this type of innovation reduces long-term hospital costs while significantly improving patient survival rates.

The transition from simple apps to AI-driven diagnostics

Tip: To attract serious capital, startups must clearly prove the transition from mere data tracking to real clinical decision support. The technological evolution from basic menstrual calendars to advanced predictive systems requires the strict application of behavioral analytics. Medical professionals demand actionable insights rather than just raw numbers on a screen.

Raw health metrics alone do not change actual treatment outcomes if they remain isolated from standard medical workflows. Integrating an AI-powered personal safety platform directly into hospital systems ensures that doctors actually utilize the collected information. Smooth data flow between the patient and the clinic ultimately dictates the commercial success of the product.

‍